Valuation: VolitionRx Limited

Market Cap 9.66M 8.45M 7.81M 7.17M 13.57M 931M 13.8M 93.16M 36.6M 455M 36.29M 35.49M 1.57B P/E 2026 *
-0.52x
P/E 2027 * -0.84x
Enterprise Value 9.66M 8.45M 7.81M 7.17M 13.57M 931M 13.8M 93.16M 36.6M 455M 36.29M 35.49M 1.57B EV / Sales 2026 *
3.9x
EV / Sales 2027 * 1.69x
Free-Float
91.38%
Yield 2026 *
-
Yield 2027 * -
1 day-1.69%
1 week-13.43%
Current month-14.07%
1 month-17.14%
3 months-67.08%
6 months-80.22%
Current year-77.31%
1 week 1.16
Extreme 1.155
1.41
1 month 1.16
Extreme 1.155
1.53
Current year 1.16
Extreme 1.155
7.73
1 year 1.16
Extreme 1.155
16
3 years 1.16
Extreme 1.155
31
5 years 1.16
Extreme 1.155
82.8
10 years 1.16
Extreme 1.155
136.8
Manager TitleAgeSince
Chief Executive Officer 55 05/10/2011
Director of Finance/CFO 56 31/01/2021
Chief Tech/Sci/R&D Officer 49 31/03/2024
Director TitleAgeSince
Director/Board Member 55 05/10/2011
Director/Board Member 77 05/10/2011
Director/Board Member 64 08/10/2019
Date Insider Type Main position Quantity % Market Cap.
17/03/26
Concord International, Inc.
OtherCompany 0 0%
17/03/26 Tax

Company Secretary

3,948 0.0029%
17/03/26 Tax

Chief Technology Officer

5,310 0.0039%
Change 5-day change 1-year change 3-year change Capi.($)
-1.69%-13.43%-91.71%-95.83% 9.66M
-0.49%-0.13%+135.28%+105.55% 4.73B
-3.49%+1.38%+104.06%+208.23% 3.54B
+1.77%+9.44%-24.24%-35.72% 2.15B
-1.69%+6.64%+108.97%-39.95% 2.08B
+35.60%+38.58%+110.10%+312.90% 2.08B
+0.71%+18.76%+181.35%-44.57% 1.05B
-2.39%+4.77%-11.88%+37.26% 878M
+5.64%+12.59%-30.82%-8.55% 535M
-3.06%+3.65%+5.11% - 478M
Average -0.72%+6.29%+48.62%+48.81% 1.75B
Weighted average by Cap. -1.10%+7.51%+89.88%+100.16%

Financials

2026 *2027 *
Net sales 2.48M 2.17M 2M 1.84M 3.48M 239M 3.54M 23.89M 9.38M 117M 9.3M 9.1M 403M 5.73M 5.01M 4.63M 4.25M 8.05M 552M 8.19M 55.27M 21.71M 270M 21.53M 21.06M 931M
Net income -22.2M -19.41M -17.95M -16.47M -31.17M -2.14B -31.71M -214M -84.08M -1.04B -83.38M -81.55M -3.61B -19.62M -17.15M -15.86M -14.55M -27.54M -1.89B -28.02M -189M -74.3M -923M -73.68M -72.06M -3.19B
Net Debt - -
Logo VolitionRx Limited
VolitionRx Limited is a multi-national company focused on advancing the science of epigenetics. The Company is dedicated to saving lives and improving outcomes for people and animals with life-altering diseases through earlier detection, as well as disease and treatment monitoring. Through its subsidiaries, it is developing and commercializing blood tests to help diagnose and monitor a range of diseases, including cancers and diseases associated with NETosis, such as sepsis. Its key pillars are Nu.Q Vet, Nu.Q NETs, Nu.Q Discover, Nu.Q Cancer, and Capture-PCR. The Nu.Q Vet Cancer Test is commercially available as a cancer screening test in dogs. Nu.Q NETs is monitoring the immune system to save lives. Nu.Q Discover is a complete solution to profiling nucleosomes. Nu.Q Cancer monitoring disease progression, response to treatment and minimal residual disease. Capture-PCRTM is isolating and capturing circulating tumor-derived DNA from plasma samples for early cancer detection.
Employees
67
Date Price Change Volume
16/07/26 US$1.160 -1.69% 124,768
15/07/26 US$1.180 -7.09% 167,899
14/07/26 US$1.270 -2.31% 161,696
13/07/26 US$1.300 -3.70% 130,769
10/07/26 US$1.350 +0.75% 395,279
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
5
Last Close Price
1.160USD
Average target price
16.97USD
Spread / Average Target
+1,362.59%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. VNRX Stock